Evidence map›Paper›PMID 39201350›Full record

ReviewInternational journal of molecular sciences2024

Post-Translational Variants of Major Proteins in Amyotrophic Lateral Sclerosis Provide New Insights into the Pathophysiology of the Disease.

Léa Bedja-Iacona, Elodie Richard, Sylviane Marouillat, Céline Brulard, Tarek Alouane, Stéphane Beltran, Christian R Andres, Hélène Blasco, Philippe Corcia, Charlotte Veyrat-Durebex and 1 more

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Léa Bedja-IaconaUMR 1253, iBraiN, Université de Tours, Inserm, 37000 Tours, France.
Elodie RichardUMR 1253, iBraiN, Université de Tours, Inserm, 37000 Tours, France.
Sylviane MarouillatUMR 1253, iBraiN, Université de Tours, Inserm, 37000 Tours, France.
Céline BrulardUTTIL, CHRU de Tours, 37000 Tours, France.
Tarek AlouaneUTTIL, CHRU de Tours, 37000 Tours, France.
Stéphane BeltranUMR 1253, iBraiN, Université de Tours, Inserm, 37000 Tours, France.
Christian R AndresUMR 1253, iBraiN, Université de Tours, Inserm, 37000 Tours, France.
Hélène BlascoUMR 1253, iBraiN, Université de Tours, Inserm, 37000 Tours, France.
Philippe CorciaUMR 1253, iBraiN, Université de Tours, Inserm, 37000 Tours, France.ORCID 0000-0002-1625-8845
Charlotte Veyrat-DurebexUMR 1253, iBraiN, Université de Tours, Inserm, 37000 Tours, France.ORCID 0000-0003-4512-2303
Patrick Vourc'hUMR 1253, iBraiN, Université de Tours, Inserm, 37000 Tours, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-translational modifications (PTMs) affecting proteins during or after their synthesis play a crucial role in their localization and function. The modification of these PTMs under pathophysiological conditions, i.e., their appearance, disappearance, or variation in quantity caused by a pathological environment or a mutation, corresponds to post-translational variants (PTVs). These PTVs can be directly or indirectly involved in the pathophysiology of diseases. Here, we present the PTMs and PTVs of four major amyotrophic lateral sclerosis (ALS) proteins, SOD1, TDP-43, FUS, and TBK1. These modifications involve acetylation, phosphorylation, methylation, ubiquitination, SUMOylation, and enzymatic cleavage. We list the PTM positions known to be mutated in ALS patients and discuss the roles of PTVs in the pathophysiological processes of ALS. In-depth knowledge of the PTMs and PTVs of ALS proteins is needed to better understand their role in the disease. We believe it is also crucial for developing new therapies that may be more effective in ALS.

Indexed as

Amyotrophic Lateral SclerosisProtein Processing, Post-TranslationalRNA-Binding Protein FUSSuperoxide Dismutase-1AcetylationAnimalsDNA-Binding ProteinsHumansMutationPhosphorylationProtein Serine-Threonine KinasesDNA-Binding ProteinsFUS protein, humanProtein Serine-Threonine KinasesRNA-Binding Protein FUSSOD1 protein, humanSuperoxide Dismutase-1TARDBP protein, humanTBK1 protein, humanALSFUSpost-translational modificationsSOD1TBK1TDP-43

Identifiers

PMID39201350
PMCPMC11354932

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.